Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CNTO's fall back plan

CNTO's fall back plan

The test of a company's fallback strategy is in the crunch. With the suspension of Centocor Inc.'s HA-1A sepsis trial last week, it remains to be seen if the company can stay alive by partnering its products, or whether it will

Read the full 454 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers